Axis-Shield signs global Holo-TC agreement:
This article was originally published in Clinica
Axis-Shield has agreed a global distribution deal with ICN Biomedicals of Costa Mesa, California, for its Holo-TC marker in radio-immunoassay form. UK-based Axis-Shield claims that the marker for the active component of vitamin B12 could eventually replace serum B12 as a standard marker for dementia, including Alzheimer's disease. Axis-Shield says that the distribution deal will enhance clinical testing and product awareness.